News Archives - Avvinity Therapeutics Limited

Nick Staples appointed as interim CEO and Jon Moore as NED

Nick Staples appointed as interim CEO and Jon Moore as NED

indigo tree2022-03-28T19:50:29+01:00November 16th, 2020|

London, UK, 16 November 2020 – Avvinity Therapeutics Limited (“Avvinity”), an immuno-oncology company developing Alphamer® immunotherapies for solid and haematological cancers, today announces the appointments of Nick Staples as interim CEO and Jon Moore as Non-Executive Director.

Avvinity’s Head of Chemistry presents at the Immuno-Oncology Summit

Avvinity’s Head of Chemistry presents at the Immuno-Oncology Summit

indigo tree2020-10-20T23:11:26+01:00October 16th, 2020|

Mel Glossop, Avvinity’s Head of Chemistry, presented at the Immuno-Oncology Summit, Europe 2020.

LifeArc invests in Avvinity Therapeutics

LifeArc invests in Avvinity Therapeutics

indigo tree2020-11-09T17:33:43+00:00October 14th, 2020|

LifeArc, an independent medical research charity, announces a £3.0m co-investment in British biotech Avvinity Therapeutics.

Avvinity Chief Scientific Officer presents at ELRIG Webinar

Avvinity Chief Scientific Officer presents at ELRIG Webinar

indigo tree2020-10-20T23:32:31+01:00October 12th, 2020|

Dr Chris Pickford, Avvinity’s Chief Scientific Officer, presented at the 2020 ELRIG webinar “Next Generation Biologics and the Future of Cancer Therapy” recently.